The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. 2 ...

The Safer Drugs Consumption Facility in Glasgow opened on 13 January, letting people take substances under supervision. The proposed value of its new contract is £4.8m - about £300,000 lower ...

Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent multiple sclerosis drug scheme, a federal appeals court said Friday. Humana ...

As I ran from interview to interview across San Francisco, I was consistently warmed by the stories I was told by biotech and ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target of $138.00. The company’s shares closed yesterday ...

Researchers report hopeful progress in efforts to find treatments for Alzheimer’s disease. They report a recent clinical trial has demonstrated the potential of focused ultrasound to safely ...

A treatment that could potentially slow the progression of amyotrophic lateral sclerosis (ALS) is being studied at the Montreal Neurological Institute-Hospital. Dr. Olivier Blanchard and his team want ...